Cargando…

Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01

Drug rash with eosinophilia with systemic symptoms (DRESS) is a serious adverse event associated with use of the glycopeptide antibiotic vancomycin. Vancomycin-induced drug rash with eosinophilia with systemic symptoms is associated with the expression of human leukocyte antigen (HLA)-A*32:01, sugge...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogese, Monday O, Lister, Adam, Gardner, Joshua, Meng, Xiaoli, Alfirevic, Ana, Pirmohamed, Munir, Park, B Kevin, Naisbitt, Dean J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404995/
https://www.ncbi.nlm.nih.gov/pubmed/34175955
http://dx.doi.org/10.1093/toxsci/kfab084
_version_ 1783746246669762560
author Ogese, Monday O
Lister, Adam
Gardner, Joshua
Meng, Xiaoli
Alfirevic, Ana
Pirmohamed, Munir
Park, B Kevin
Naisbitt, Dean J
author_facet Ogese, Monday O
Lister, Adam
Gardner, Joshua
Meng, Xiaoli
Alfirevic, Ana
Pirmohamed, Munir
Park, B Kevin
Naisbitt, Dean J
author_sort Ogese, Monday O
collection PubMed
description Drug rash with eosinophilia with systemic symptoms (DRESS) is a serious adverse event associated with use of the glycopeptide antibiotic vancomycin. Vancomycin-induced drug rash with eosinophilia with systemic symptoms is associated with the expression of human leukocyte antigen (HLA)-A*32:01, suggesting that the drug interacts with this HLA to activate CD8+ T cells. The purpose of this study was to utilize peripheral blood mononuclear cell from healthy donors to: (1) investigate whether expression of HLA-A*32:01 is critical for the priming naïve of T cells with vancomycin and (2) generate T-cell clones (TCC) to determine whether vancomycin exclusively activates CD8+ T cells and to define cellular phenotype, pathways of drug presentation and cross-reactivity. Dendritic cells were cultured with naïve T cells and vancomycin for 2 weeks. On day 14, cells were restimulated with vancomycin and T-cell proliferation was assessed by [(3)H]-thymidine incorporation. Vancomycin-specific TCC were generated by serial dilution and repetitive mitogen stimulation. Naïve T cells from HLA-A*02:01 positive and negative donors were activated with vancomycin; however the strength of the induced response was significantly stronger in donors expressing HLA-A*32:01. Vancomycin-responsive CD4+ and CD8+ TCC from HLA-A*32:01+ donors expressed high levels of CXCR3 and CCR4, and secreted IFN‐γ, IL-13, and cytolytic molecules. Activation of CD8+ TCC was HLA class I-restricted and dependent on a direct vancomycin HLA binding interaction with no requirement for processing. Several TCC displayed cross-reactivity with teicoplanin and daptomycin. To conclude, this study provides evidence that vancomycin primes naïve T cells from healthy donors expressing HLA-A*32:01 through a direct pharmacological binding interaction. Cross-reactivity of CD8+ TCC with teicoplanin provides an explanation for the teicoplanin reactions observed in vancomycin hypersensitive patients.
format Online
Article
Text
id pubmed-8404995
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-84049952021-09-01 Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01 Ogese, Monday O Lister, Adam Gardner, Joshua Meng, Xiaoli Alfirevic, Ana Pirmohamed, Munir Park, B Kevin Naisbitt, Dean J Toxicol Sci Immunotoxicology Drug rash with eosinophilia with systemic symptoms (DRESS) is a serious adverse event associated with use of the glycopeptide antibiotic vancomycin. Vancomycin-induced drug rash with eosinophilia with systemic symptoms is associated with the expression of human leukocyte antigen (HLA)-A*32:01, suggesting that the drug interacts with this HLA to activate CD8+ T cells. The purpose of this study was to utilize peripheral blood mononuclear cell from healthy donors to: (1) investigate whether expression of HLA-A*32:01 is critical for the priming naïve of T cells with vancomycin and (2) generate T-cell clones (TCC) to determine whether vancomycin exclusively activates CD8+ T cells and to define cellular phenotype, pathways of drug presentation and cross-reactivity. Dendritic cells were cultured with naïve T cells and vancomycin for 2 weeks. On day 14, cells were restimulated with vancomycin and T-cell proliferation was assessed by [(3)H]-thymidine incorporation. Vancomycin-specific TCC were generated by serial dilution and repetitive mitogen stimulation. Naïve T cells from HLA-A*02:01 positive and negative donors were activated with vancomycin; however the strength of the induced response was significantly stronger in donors expressing HLA-A*32:01. Vancomycin-responsive CD4+ and CD8+ TCC from HLA-A*32:01+ donors expressed high levels of CXCR3 and CCR4, and secreted IFN‐γ, IL-13, and cytolytic molecules. Activation of CD8+ TCC was HLA class I-restricted and dependent on a direct vancomycin HLA binding interaction with no requirement for processing. Several TCC displayed cross-reactivity with teicoplanin and daptomycin. To conclude, this study provides evidence that vancomycin primes naïve T cells from healthy donors expressing HLA-A*32:01 through a direct pharmacological binding interaction. Cross-reactivity of CD8+ TCC with teicoplanin provides an explanation for the teicoplanin reactions observed in vancomycin hypersensitive patients. Oxford University Press 2021-06-27 /pmc/articles/PMC8404995/ /pubmed/34175955 http://dx.doi.org/10.1093/toxsci/kfab084 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Society of Toxicology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Immunotoxicology
Ogese, Monday O
Lister, Adam
Gardner, Joshua
Meng, Xiaoli
Alfirevic, Ana
Pirmohamed, Munir
Park, B Kevin
Naisbitt, Dean J
Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01
title Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01
title_full Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01
title_fullStr Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01
title_full_unstemmed Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01
title_short Deciphering Adverse Drug Reactions: In Vitro Priming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01
title_sort deciphering adverse drug reactions: in vitro priming and characterization of vancomycin-specific t cells from healthy donors expressing hla-a*32:01
topic Immunotoxicology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404995/
https://www.ncbi.nlm.nih.gov/pubmed/34175955
http://dx.doi.org/10.1093/toxsci/kfab084
work_keys_str_mv AT ogesemondayo decipheringadversedrugreactionsinvitroprimingandcharacterizationofvancomycinspecifictcellsfromhealthydonorsexpressinghlaa3201
AT listeradam decipheringadversedrugreactionsinvitroprimingandcharacterizationofvancomycinspecifictcellsfromhealthydonorsexpressinghlaa3201
AT gardnerjoshua decipheringadversedrugreactionsinvitroprimingandcharacterizationofvancomycinspecifictcellsfromhealthydonorsexpressinghlaa3201
AT mengxiaoli decipheringadversedrugreactionsinvitroprimingandcharacterizationofvancomycinspecifictcellsfromhealthydonorsexpressinghlaa3201
AT alfirevicana decipheringadversedrugreactionsinvitroprimingandcharacterizationofvancomycinspecifictcellsfromhealthydonorsexpressinghlaa3201
AT pirmohamedmunir decipheringadversedrugreactionsinvitroprimingandcharacterizationofvancomycinspecifictcellsfromhealthydonorsexpressinghlaa3201
AT parkbkevin decipheringadversedrugreactionsinvitroprimingandcharacterizationofvancomycinspecifictcellsfromhealthydonorsexpressinghlaa3201
AT naisbittdeanj decipheringadversedrugreactionsinvitroprimingandcharacterizationofvancomycinspecifictcellsfromhealthydonorsexpressinghlaa3201